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A B S T R A C T
Heat shock proteins (HSPs) are chaperones that catalyze the refolding of denatured proteins. In addition to their
ability to prevent protein denaturation and aggregation, the HSPs have also been shown to modulate many
signaling pathways. Among HSPs, the inducible 70 kDa HSP (HSP70) has especially been shown to improve
neurological outcome in experimental models of brain ischemia and injury. HSP70 can modulate various aspects
of the programmed cell death pathways and inﬂammation. This review will focus on potential mechanisms of the
neuroprotective eﬀects of HSP70 in stroke and brain trauma models. We also comment on potential ways in
which HSP70 could be translated into clinical therapies.
1. Introduction
The brain undergoes a stress response after cerebral ischemia (CI)
and traumatic brain injury (TBI). One of the most highly upregulated
stress proteins are the heat shock proteins (HSPs). These proteins were
so named, as they were noted to be highly induced by heat stress. They
are a family of proteins identiﬁed by their molecular weight, and pos-
sess chaperone functions for which they have been described to assist in
protein folding, protein degradation and other related activities. Under
conditions of cell stress or injury, these actions protect the cell by
preventing the aggregation of damaged proteins and promote the as-
sembly of nascent proteins. HSP70, in concert with its co-chaperone
HSP40, is a key HSP family member involved in the degradation of
damaged proteins [1]. In acute brain injury models, many studies have
reported that in addition to typical chaperone functions, HSP70 inter-
rupted multiple cell death pathways, such as classical apoptosis, ne-
crosis, and inﬂammation [2,3]. HSP70 has now been shown to interrupt
several of these pathways and ultimately leads to improvements in
neurological outcome [4]. We will discuss the mechanism of HSP70
neuroprotection in brain injury along with potential pharmacological
means of applying HSP70 at the clinical level.
2. Heat shock proteins
At the onset of brain injury, synthesis of most cellular proteins is
downregulated. However, there is a small class of proteins which are
actually upregulated and have collectively been referred to as stress
proteins. HSPs are named in accordance with their molecular mass. The
constitutive HSPs perform cellular housekeeping functions and include
HSP90, HSP40 and HSP70 [5]. Inducible forms include inducible
HSP70 has also been referred to as HSP70i or HSP72, but here we will
refer to it as HSP70. Inducible HSPs are upregulated in response to cell
stress, including thermal, ischemic and traumatic stresses to the tissue.
While previously debated whether their upregulation reﬂected cell
stress, or actively represented a cytoprotective mechanism, work over
the past few decades now indicate that HSPs represent the latter [6]
In the brain and in cultures of brain cells, heat and ischemic stress
have been shown by several labs to trigger robust induction of HSP70
[7]. As such, HSP70 has been the most widely studied stress protein in
terms of its neuroprotective properties. HSP70 interacts with hydro-
phobic peptide segments of unstructured proteins in an ATP-dependent
manner. HSP70 also contains a C-terminal substrate-binding domain
which identiﬁes unstructured polypeptide segments, and an N-terminal
ATPase domain which assists in protein folding, alternating between an
ATP-bound open state with low substrate aﬃnity and an ADP-bound
closed state with high substrate aﬃnity [8]. In studies of CI, HSP70 was
ﬁrst observed to be induced in brain regions that were relatively re-
sistant to ischemic insults. Thus, the notion of a ‘molecular penumbra’
was introduced, and raised questions as to whether this expression was
an epiphenomenon of the injury, or an active participant in cell survival
[9]. By showing that speciﬁcally increasing HSP70, several labs have
shown that Hsp70 protects the brain and brain cells against
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experimental brain insults including CI and TBI [4,10–13]. Conversely,
downregulation of HSP70 results in the opposite. Consistent with its
chaperone functions, induction of HSP70 has also been shown to reduce
protein aggregation and the development of intracellular inclusions,
while preventing the redistribution of ubiquitin [14,15]. HSP70 has
also been shown to mediate cytoprotection by interfering and reg-
ulating apoptotic and immune pathways.
3. Heat Shock Protein 70 induction and the unfolded protein
response
HSP70 induction occurs though the activity of heat shock factor 1
(HSF1), which is a transcription factor that binds to HSP70’s 5’promoter
region, as well as that of all HSP genes [16]. HSPs are normally located
intracellularly and are bound to HSF1 under homeostatic conditions
[17]. When the cell experiences stress, such as trauma, ischemia, and
other denaturing stimuli which lead to unfolded proteins, HSPs dis-
sociate from HSF, thus allowing HSPs to bind denatured or aggregated
proteins. HSPs are also capable of binding other proteins involved in
cell death pathways. Following such stresses, dissociated HSF translo-
cates to the nucleus where it is phosphorylated by protein kinase C, and
forms activated trimers. These trimers then bind to heat shock elements
(HSEs), which are DNA sequence motifs present within the heat shock
gene and are recognized by HSFs. Once HSFs bind to HSEs, more
synthesis of HSP70 protein occurs [16]. HSP90 acts as an inhibitor of
HSP70 induction, as HSP90 is normally bound to HSF1 in the resting
state. During the stress response, HSP90 dissociates from HSF1, thus
liberating it to bind HSEs with subsequent upregulation of HSP70 [18].
HSP70 protein, once synthesized in high quantities following the
initial stress response, acts in concert with HSP40, HSP90 and ATP to
restore denatured proteins to their property tertiary architecture. These
proteins form a complex which binds denatured proteins and, through
chaperone functions, lead to their repair and refolding. This occurs
through several cycles whereby the chaperone complex attempts to
refold the protein. HSP70 acts indirectly through its cochaperones CHIP
(C-terminus of HSP70/HSC70 interacting protein) and BAG-1 (Bcl-
2–associated athanogene-1) [19]. CHIP is a ubiquitin ligase that inter-
acts with HSP70 and sequesters and ubiquitinates unfolded proteins,
followed by their degradation [20]. CHIP may also enhance HSP70
induction under conditions of cell stress, thus maintaining protein
homeostasis by regulating chaperone levels [21]. BAG-1 is another
HSP70 cochaperone involved in protein degradation. CHIP and BAG-1
interact directly, and their co-expression increases protein degradation
[22]. Therefore, these proteins act together to shift chaperone activity
from protein folding to protein degradation. [23–25]. Hsp90 also plays
a role in protein degradation, although its actions are opposite those of
HSP70, where HSP90 seems to inhibit substrate ubiquitination and
degradation [26,27].
4. HSP70 in CI and TBI
HSP70 induction has been shown to confer neuroprotection against
many acute brain insults, of which we will largely focus on CI and TBI.
HSP70 upregulation has been achieved in experimental studies through
the use of genetic models that either overexpress or are deﬁcient in
HSP70. HSP70 can also be manipulated via viral vector-mediated
HSP70 overexpression, siRNA-mediated downregulation or induction
via the application of sublethal heat stress. Many experimental studies
have now established that HSP70 induction led to neuroprotection in
variety of acute neurological injuries.
Cessation or reduction of cerebral blood ﬂow followed by reperfu-
sion of neural tissue initiates an array of signaling pathways, including
excitotoxicity to apoptosis, all of which ultimately lead to cellular da-
mage and death. Under non stressful, homeostatic conditions, very little
inducible HSP70 is present; however, it is robustly increased following
injury, and is perhaps the most highly induced proteins expressed in
response to such stress. Early studies showed a correlation between
HSP70 overexpression and neuroprotection. In experimental stroke
models, initial HSP70 induction was observed within neurons of the
penumbra [9], or brain regions immediately adjacent to the infarct, and
thought to be likely to survive CI. This was followed by HSP70 induc-
tion within astrocytes and microglia as well as endothelial cells of the
cerebral vasculature [9], cell types which have been thought to be more
resistant to CI compared to neurons. Thus, HSP70 was thought to play a
role in protecting cells from ischemic insults compared to cells and
brain regions where HSP70 expression was lower or absent. On the
other hand, critics of this model have argued that HSP70 may simply be
a marker of stressed cells with nothing to do with saving the cell from a
likely death. However, when HSP70 was overexpressed in neurons and
astrocytes using viral vectors, HSP70 overexpressing neurons and as-
trocytes were more resistant to ischemic and ischemia-like insults [8].
Similarly, transgenic mice that overexpressed HSP70 in the brain had
better neurological outcomes following experimental CI and TBI com-
pared to wildtype mice. Conversely, HSP70 deﬁciency worsened out-
come in similar models [10,28]. Further, three diﬀerent studies in
wildtype animals were given HSP70 protein in an attempt to boost
brain levels [29–31], and in each of these studies, animal subjected to
stroke and treated with HSP70 had better functional and histological
outcomes.
With many similarities to CI, TBI causes mechanical damage to
brain cells and their vessels. This mechanical damage triggers cell death
cascades which takes place over the ensuring hours or days [32–34].
TBI pathophysiology has substantial overlap with that seen in stroke,
including oxidative stress, excitotoxicity, neuroinﬂammation and
edema. In TBI models, several studies showed a neuroprotective eﬀect
of HSP70. Our lab reported that transgenic mice overexpressing HSP70
and subjected to experimental TBI via controlled cortical impact (CCI),
had better neurological outcomes compared to wildtype controls [4].
Conversely, HSP70 deﬁcient mice had worse outcomes compared to
both wildtype and HSP70 transgenic mice. Further, HSP70 over-
expression not only led to smaller lesions sizes and better neurological
function, it also reduced the extent of brain hemorrhage and blood
brain barrier (BBB) disruption. The reduction in BBB damage and he-
morrhage correlated to suppression of MMP-2 and -9 [4,35]. A related
study in a model of neurodegeneration similarly showed that HSP110
or HSP70 deﬁcient mice had worse outcomes compared to wildtype,
while treatment with HSP70/HSP110 inducers Celastrol and BGP-15
improved neurological outcome [36]. HSP70 overexpression also pro-
tected against brain contusion, edema, neuronal apoptosis, and neuro-
logical motor deﬁcits in a rodent hemorrhagic shock model with carotid
occlusion [37].
Not all studies showed beneﬁcial eﬀects of HSP70 in acute neuro-
logical injury models. An early study from our laboratory showed no
eﬀect of HSP70 overexpression in a transgenic mouse model of stroke,
although it did protect astrocytes derived from the same mouse strain
[38]. It should be noted that this particular HSP70 transgenic model
had somewhat lower levels of HSP70 overexpression (approximately
2.5 times higher than wildtype controls) compared to other transgenic
models where HSP70 overexpression was at least ten fold higher
[39,40]. HSP70 has also not been shown to improve outcomes in other
neurological conditions such as the synucleinopathies which are
thought to cause Parksinson’s disease and related conditions [41,42].
Further, as elaborated in more detail below, extracellular HSP70 has
the potential to worsen outcomes from stroke, as it is known to act on
the pro-inﬂammatory Toll-like receptor-4 (TLR4). In fact, in a related
model of retinal ischemia-reperfusion injury, extracellular HSP70 was
identiﬁed as a factor which promoted inﬂammation-induced retinal
neuron death [43]. Thus, the beneﬁcial properties of HSP70 may be
limited by the levels to which it can be increased, the nature of the
insult or disease as well as the compartment in which it acts.
HSPs have also been shown to interfere with speciﬁc cell death
pathways, of which programmed cell death (apoptosis) and
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inﬂammation have been the best studied. The precise mechanism by
which HSPs modulate these pathways is unclear, but may simply bind
stressed or stress-associated proteins in an indiscriminate and parallel
manner, as these actions occur within similar time frames and similar
brain regions. The following sections will review how HSPs have been
shown to modulate these pathways.
5. Heat shock protein 70 interrupts several cell death signaling
pathways
In addition to its classic chaperone functions related to protein
folding and aggregation, HSP70 has been shown to directly interfere
with multiple cell death pathways. After brain injury, apoptotic or
programmed cell death has been observed in parallel with necrosis. In
CI, the best studied pathways include the intrinsic apoptotic pathway,
which occurs within the cell’s mitochondria [44], and the extrinsic
pathway, which is initiated by ligand interactions at surface receptors
[45]. In CI and TBI, apoptosis occurs following reactive oxygen species
signaling, death receptor ligation, genomic damage, protease activation
and others. Many studies have now documented that HSP70 directly or
indirectly interferes with both pathways.
The intrinsic apoptotic pathway originates from mitochondrial
stress/damage due to the acute brain insult. Following brain injury,
mitochondria release cytochrome c, which combines with caspase-9 to
form the apoptosome, followed by activation of executor caspases
causing apoptotic death. Apoptosis may also proceed through a caspase-
independent pathway which is initiated when injured mitochondria
release apoptosis inducing factor (AIF). The Bcl-2 family members
diﬀerentially aﬀect this pathway through direct interaction with cyto-
chrome c and AIF release. Bcl-2 family members include three sub-
groups: the anti-apoptotic proteins (Bcl-2, Bcl-XL, and Bcl-w), the pro-
apoptotic proteins (Bax and Bak), and the BH3-only proteins (Bad, Bid,
Bim, Noxa, and PUMA). Bcl-2 family members participate in both
deaths promoting and death salvaging activities. BH3-only proteins
lead to brain cell death following ischemic insults through interactions
with other Bcl-2 proteins [46]. HSP70 interferes at multiple points
within the intrinsic apoptotic pathway. It interacts with several proteins
of the apoptosis cascade, both upstream [47,48] and downstream of the
mitochondria [49]. In experimental stroke, HSP70 interrupts cyto-
chrome c translocation from the mitochondria to the cytosol [35,50]
and AIF translocation from the mitochondria to the nucleus. In a cell
free system, HSP70 interfered with recruitment of procaspase-9 and
apoptosis protease activating factor-1 (Apaf-1) into the apoptosome
[51]. HSP70 similarly prevented mitochondrial release of another pro-
apoptotic protein, Smac/DIABLO [52]. The mitochondrial HSPs,
HSP70, HSP75 and mortalin assistants which function by maintaining
mitochondrial membrane potential, preserve mitochondrial function
and protein import [53]. In a model of HSP70 protection in astrocytes,
HSP70 was also correlated to higher ATP levels [54] along with reduced
oxidative stress and preserved mitochondrial membrane potentials [55]
and glutathione [56,1]. In a related study of myocardial ischemia,
overexpression of HSP70 was found to reduce oxidative stress by in-
creasing mitochondrial manganese superoxide dismutase (SOD2) [57].
Bcl-2 is central to preventing intrinsic apoptosis, as it blocks mi-
tochondrial release of cytochrome c and AIF. HSP70 increases levels of
Bcl-2 in some disease models, including ischemic neurons [17]. Some
investigators have proposed that the balance between Bcl-2’s pro- and
anti-apoptotic members determines whether cells undergo apoptosis or
survival [58]. Thus, it is conceivable that HSP70 overexpression could
decrease apoptosis upstream of mitochondria via increased Bcl-2 levels.
As such, HSP70 has been shown to reduce heat shock-induced apoptosis
by blocking translocation of pro-apoptotic Bax from the cytosol to the
mitochondrial where it aids in forming the mitochondrial transition
pore (MTP) [48], and the MTP is opposed by anti-apoptotic Bcl-2. In-
corporation of Apaf-1 into the apoptosome is required for caspase-9
activation, and HSP70 has been shown to interfere with this [51],
although this has not been consistently demonstrated [47].
The extrinsic apoptotic pathway, which relies on the engagement of
receptors located on the cell’s surface, is also referred to as the “death
receptor pathway". Ligation of these so-called death receptors leads to
caspase-8 and caspase-10 activation, which triggers a cascade that ul-
timately leads to activation of eﬀector caspases, particularly caspase-3
[59]. Several such death receptors have been identiﬁed, but the most
widely studied in brain ischemia and injury include tumor necrosis
factor receptor (TNFR) and Fas (also known as CD95). These receptors
are bound by their respective ligands TNF (and related TNF family
molecules) and fas ligand (FASL) [60]. FasL initiates apoptosis by
binding to Fas, followed by the recruitment of its adaptor protein Fas-
associated death domain protein (FADD). FADD then binds procaspase-
8 at its death eﬀector domain thus forming a 4 molecule complex that is
referred to as a death-inducing signaling complex (DISC). The DISC
leads to activation of procaspase-8 to caspase-8 followed by activation
of caspase−10, which in turn activates eﬀector caspase-3 [61].
HSP70 has also been shown to interact with this extrinsic death
receptor pathway at several levels. It can prevent receptor-mediated
apoptosis through its ability to bind death receptors TNF-related
apoptosis-inducing ligand-I (TRAIL-RI, also known as death receptor-4
DR4) and TRAIL-RII (also known as DR5). When TRAIL-RI and TRAIL-
RII are bound by its ligand TRAIL, TNF-related apoptosis occurs, but
HSP70 has been shown to interrupt receptor binding as well as DISC
formation [62,63]. Downstream of DISC formation and caspase 8 acti-
vation, HSP70 can prevent apoptosis by inhibiting BID activation [64].
Recently, it has been shown that dynamin, a GTPase involved in en-
docytosis, can also traﬃc Fas via the endoplasmic reticulum to the cell’s
surface [65]. Once expressed on the cell surface, Fas can trigger
apoptosis when bound by its ligand FasL. We recently showed that
HSP70 may prevent movement of Fas from the cytosol to the cell sur-
face by interacting with both dynamin and Fas, and that overexpression
of HSP70 as well as dynamin inhibition improved neurological outcome
in CI [10]. Thus, HSP70 appears to aﬀect both apoptotic pathways at
multiple points in the cascades.
6. Heat shock protein 70 modulates inﬂammation
Inﬂammation follows both CI and TBI, and begins with activation of
the brain’s immune cell, or microglia. This is soon followed by an inﬂux
of circulating leukocytes into the injured brain [66–68]. Once activated,
these immune cells elaborate several cytotoxic agents such as reactive
species, cytokines, glutamate and proteases, all of which have been
implicated in exacerbating cell death [69]. Following brain injury,
HSP70 has been shown to regulate inﬂammation via pro- and anti-in-
ﬂammatory mechanisms depending on its location within or outside of
the cell. When HSP70 is intracellular, it seems to inhibit immune re-
sponses, whereas extracellularly, it seems to potentiate them.
Its anti-inﬂammatory activities include its ability to inhibit tran-
scription and translation of immune molecules. HSP70 has been shown
to interact with and inhibit activation of the pro-inﬂammatory tran-
scription factor nuclear factor-kappaB (NF-kB) and its target genes. It
has also been shown to prevent processing of matrix metalloproteinases
(MMPs) to their active form. Intracellular overexpression of HSP70 by
genetic manipulation or induction by heat stress has been shown to
reduce production of nitric oxide and expression of inducible nitric
oxide synthase (iNOS) while decreasing NF-kB activation [70]. Heat
stress, which induces HSP70, has also been correlated to decreased
secretion of proinﬂammatory cytokine TNF-α and reduced generation
of reactive oxygen species (ROS). HSP70 induced in macrophages has
similarly been shown to inhibit responsiveness to inﬂammatory cyto-
kines TNF-α and interleukin (IL)-1, IL-10 and IL-12 [71,3,72]. In line
with these observations, HSP70 induction in a model of intracerebral
hemorrhage decreased TNF-α expression, preserved blood brain barrier
(BBB), reduced brain edema, and improved neurological function [73].
HSP70 induction by heat stress in phagocytes also inhibited NADPH
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oxidase (NOX) activity in neutrophils with subsequent reduction of
superoxide. It also enhanced expression of superoxide dismutase (SOD),
an endogenous superoxide scavenger. In a similar model of heat stress
[74], HSP70 induction inhibited phosphorylation of inﬂammatory
transcription factors or their partner molecules IkB, JNK and p38.
HSP70 induction also blunted the ability of DNA to bind transcription
factors, such as NF-kB, activator portien-1 and signal transducer and
activator of transcription factor 1 (STAT-1), and led to the down-
regulation of several pro-inﬂammatory genes [75]. Other studies have
also shown that prior-heat stress leads to the inhibition of the in-
ﬂammatory response, and this inhibition was associated with upregu-
lation of HSP70 and decreased nuclear NF-kB translocation [76,77].
HSP70 was shown to interact with inhibitor of kB (IkB) by preventing
its phosphorylation, thus inhibiting NF-kB by preventing its dissociation
from it [78]. Other studies have shown that HSP70 inhibits NF-kB by
directly binding it and its regulatory proteins in stroke and neuroin-
ﬂammation models [40,79]. How HSP70 inhibits NF-kB may depend on
the nature of the stimulus. When pro-inﬂammatory cytokine TNF-α was
used to induce cell death, HSP70 directly inhibited the IkB kinase (IKK),
the kinase which phosphorylates and activates IkB [80]. However, in a
stroke model, HSP70 directly associated with NF-kB and IkB, and pre-
vented IkB phosphorylation by IKK in an indirect manner [40]. In both
studies, NF-kB inhibition by HSP70 led to downstream reduction in
both transcription and translation of NF-kB’s target genes, and led to
neuroprotection. One such gene inhibited by HSP70 and also regulated
by NF-kB is MMP-9. Cultured astrocytes overexpressing HSP70 exposed
to ischemia-like insults had reduced MMP-9 mRNA, and is consistent
with the notion that HSP70 regulates inﬂammation at the transcrip-
tional level [81]. However, HSP70 overexpressed in astrocytes also
decreased MMP-2 expression, which is not regulated by NF-kB [81].
MMP-2 is known to be regulated by STAT-1 [82], which HSP70 and
heat stress are also known to inhibit [75,83]. HSP70 also seems to act at
the post translational level where it was found to inhibit processing of
MMPs to their active forms. Another report further linked HSP70 to
neuroprotection via the micro RNA miR-122 [84]. In this study, a
beneﬁcial eﬀect of miR-122 was observed in experimental stroke, and
this depended on HSP70’s ability to inhibit NF-kB. Thus, HSP70 can
interrupt inﬂammatory signaling and inﬂammatory molecules at mul-
tiple levels.
Extracellular HSP70 has also been shown to modulate immune re-
sponses, but in a manner opposite to intracellular HSP70 [85]. In the
extracellular environment, HSP70 appears to potentiate at immune
responses. In models of adaptive immunity, exogenous administration
of HSP70 in culture or immunization of mice was shown to potentiate
T-cell responses indicating that HSP70 acts as an immune adjuvant [86]
[87]. Extracellular HSP70 can also interact with the receptors on
macrophages and dendritic cells, and aid in antigen presentation [88].
In addition to adaptive immune activities, extracellular HSP70 has also
been shown to participate in innate immune activities. It has been
shown to interact with microglia and macrophages through Toll-like
receptors (TLRs). Some work has shown that HSP70 can bind TLRs and
activate NF-kB [89]. HSP60 and HSP90 have also been shown to in-
teract with TLR2 and TLR4 [90]. However, some of this latter work may
have resulted from preparations of recombinant HSPs containing low
levels of endotoxin, which can also TLR4 [91]. However, there are no
published works of extracellular HSPs in CI or TBI.
7. Pharmacological therapy of heat shock protein 70 in brain
injury
While many laboratory studies of neuroprotection by HSP70 have
largely used genetic manipulation to upregulate the protein, pharma-
cological means of inducing HSP70 would have wider translational
relevance. A few studies have explored the pharmacological induction
of HSP70 in focal and global CI models [92,93] and experimental TBI
[94,92,93]. The majority of approaches used Hsp90 inhibitors, which,
by liberating HSF, upregulated HSP70. The most studied of these has
been geldanamycin (GA), which has been shown to both induce HSP70
in the brain and lead to better neurological outcomes from experi-
mental stroke. However, GA has since been found to be less than ideal
for clinical translation due to hepatoxicity [95]. As such, GA analogue
17-allylamino-17-demethoxygeldanamycin (17-AAG) has been shown
to have similar HSP90 inhibitory functions with less toxicity. 17-AAG
has been studied in clinical trials through IV administration for cancer
therapy [95,96]. Work from our group has shown that when 17-AAG is
given parenterally, it causes HSP70 induction in the brain, and leads to
similar beneﬁcial eﬀects in experimental TBI as seen in HSP70 over-
expressing mice. 17-(2-dimethylaminoethyl) amino-17-demethox-
ygeldanamycin (17-DMAG), also a GA derivative, is thought to have
wider tissue distribution, and was studied in an experimental stroke
model where it was shown to improve neurological outcome through
HSP70 induction. The beneﬁcial eﬀect was also correlated to reduced
inﬂammation through inhibition of microglial activation and phos-
phorylation NF-kB’s inhibitor protein IkB [97].
Other HSP70-inducing compounds include the purine-based com-
pounds, the resorcinols. While this class has been studied for cancer
treatment, and a few have moved to clinical trial, none have been
studied in brain injury models to date [96,16]. A few studies have been
carried out in stroke models with another HSP70 inducer, geranylger-
anylacetone (GGA), previously studied for treatment of gastric ulcers.
Administration of GGA in experimental stroke showed similar bene-
ﬁcial eﬀects and this was associated with an anti-inﬂammatory eﬀect
through up-regulation of HSP70 by inducing protein kinase C [98,99].
In a TBI model, pretreatment with GGA similarly led to a neuropro-
tective eﬀect by reducing neuronal apoptosis and inhibiting microglial
activation [100]. As GGA may be the best tolerated of the HSP70 in-
ducing drugs, this approach may be the most promising as far as
translating a treatment to patients suﬀering stroke or TBI.
While most pharmacological approaches that have been studied in
humans for other indications have focused on HSP90 inhibitors to up-
regulate HSP70, there are other approaches that deserve investigation.
Other partners in the HSP pathways have the potential to be targeted.
For example, small molecules to act as HSF mimics could be used to
pharmacologically upregulate HSP70, rather than relying on suﬃcient
endogenous HSFs to stimulate HSP70 production. A limitation to cur-
rent HSP90 inhibitors and other means of inducing HSP70 as it pertains
to acute neurological diseases is that generation of HSP70 protein may
take hours to produce, and it is well known that very early intervention
increases the likelihood of a good outcome. Administering recombinant
HSP70 protein itself would circumvent this time sensitive problem. In
fact, a few preclinical studies of stroke delivered HSP70 protein by
conjugating it to carrier molecules to facilitate brain penetration after
parenteral administration [29–31]. In one report, HSP70 was con-
jugated to the brain penetrating HIV TAT protein [29], while in an-
other, HSP70 was conjugated a fragment of an anti-DNA antibody (mAb
3E10 or Fv) which is thought to penetrate cell membranes [30]. Other
areas of investigation in the treatment of stroke and brain trauma in-
clude targeting the chronic phases of injury, and include employing cell
based treatments. One issue surrounding cell based therapies such as
stem cells, is that the transferred cells seem to die or disappear after
administration. Thus, one possibility may be to generate stem cells that
overexpress HSPs in order to improve their survival.
8. Conclusions
HSPs, particularly HSP70, has been shown to directly engage in
multiple mechanisms of neuroprotection in experimental models of
acute brain injury. HSPs appear to have multifaceted mechanisms of
protection by interfering with several aspects of acute brain injury.
Several compounds have now been shown to pharmacologically induce
HSP70 in the brain, and suggests that this may be a viable approach
with potential for clinical translation. As recent advances in acute
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stroke treatment include revascularization strategies, there may be re-
newed interest in neuroprotection as adjunctive agents in at least stroke
patients. Thus, it seems that clinical studies should be the next step.
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